Next Article in Journal
Functional, Antioxidant, Antibacterial, and Antifungal Activity of Edible Flowers
Previous Article in Journal
ZnO NPs Impair the Viability and Function of Porcine Granulosa Cells Through Autophagy Regulated by ROS Production
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ellagic Acid Reduces Cadmium Exposure-Induced Apoptosis in HT22 Cells via Inhibiting Oxidative Stress and Mitochondrial Dysfunction and Activating Nrf2/HO-1 Pathway

1
National Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
2
Technology Innovation Center for Food Safety Surveillance and Detection (Hainan), Sanya Institute of China Agricultural University, Sanya 572025, China
3
Key Biology Laboratory of Chinese Veterinary Medicine, Ministry of Agriculture and Rural Affairs, Beijing 100193, China
*
Authors to whom correspondence should be addressed.
Antioxidants 2024, 13(11), 1296; https://doi.org/10.3390/antiox13111296
Submission received: 11 September 2024 / Revised: 22 October 2024 / Accepted: 23 October 2024 / Published: 25 October 2024
(This article belongs to the Topic Recent Advances in Veterinary Pharmacology and Toxicology)

Abstract

:
Exposure to cadmium sulfate (CdSO4) can lead to neurotoxicity. Nevertheless, the precise molecular mechanisms underlying this phenomenon remain unclear, and effective treatment strategies are scarce. This study explored the protective effects of ellagic acid (EA), a natural polyphenolic compound, against CdSO4 exposure-induced neurotoxicity in HT22 cells and the underlying molecular mechanisms. Our findings demonstrated that exposure of HT22 cells to CdSO4 resulted in apoptosis, which was effectively reversed by EA in a dose-dependent manner. EA supplementation also decreased reactive oxygen species (ROS) and mitochondrial ROS production, reduced malondialdehyde (MDA) levels, and restored the activities of superoxide dismutase (SOD) and catalase (CAT). Additionally, EA supplementation at 5–20 μM significantly counteracted Cd-induced the loss of mitochondrial membrane potential and the decrease of ATP and reduced the ratio of Bax/Bcl-2 and cleaved-caspase-3 protein expression. Furthermore, EA supplementation resulted in the upregulation of Nrf2 and HO-1 protein and mRNAs while simultaneously downregulating the phosphorylation of JNK and p38 proteins. The pharmacological inhibition of c-Jun N-terminal kinase (JNK) partially attenuated the activation of the Nrf2/HO-1 pathway induced by CdSO4 and exacerbated its cytotoxic effects. In conclusion, our findings suggest that ethyl acetate (EA) supplementation offers protective effects against CdSO4-induced apoptosis in HT22 cells by inhibiting oxidative stress and activating the Nrf2 signaling pathway. Furthermore, the activation of the JNK pathway appears to play a protective role in CdSO4-induced apoptosis in HT22 cells.

1. Introduction

Cadmium (Cd) is a prevalent non-essential heavy metal known to have highly toxic effects on both humans and animals [1]. Cd has been ranked 7th in the hazardous waste priority list according to the U.S. Environmental Protection Agency’s Superfund, based on its level of toxic risk [1]. The World Health Organization and The International Agency for Research on Cancer (IARC) have both classified Cd as a human carcinogen [2]. Previous studies from animal models and in vitro cell models showed that Cd exposure could cause multiple toxic effects, including hepatoxicity, nephrotoxicity, reproductive toxicity, immunotoxicity, and gastrointestinal toxicity [3,4,5,6,7]. Cd has the potential to penetrate the blood-brain barrier (BBB), leading to its accumulation in the central nervous system and ultimately causing neurotoxicity. A recent epidemiological investigation showed that environmental exposure to Cd may be a risk factor for Alzheimer’s disease in humans [8]. Epidemiologic studies have indicated that Cd exposure is positively corrected with Alzheimer’s disease [9,10]. For example, a meta-analysis showed that Cd concentrations in whole blood, serum, or plasma samples of Alzheimer’s disease patients were significantly higher than those in controls [10]. In a mouse model, Cd exposure could result in abnormal neurobehavioral changes (such as movement disorders, attention deficits, headaches, and cognitive dysfunction) and pathological injury in brain tissues [11,12,13]. Hence, investigating the potential health risks of environmental Cd exposure in the nervous system and understanding the underlying molecular mechanisms are of great importance.
The precise molecular mechanisms underlying neurotoxicity induced by Cd exposure are not yet fully elucidated. Deng et al. found that chronic exposure to Cd could result in cognitive function impairment in male mice by promoting mitochondrial fission and dysfunction within brain tissues [1]. It was reported that Cd exposure could affect the function of mitochondria by blocking the electron transport chain and reducing membrane potential in neuronal cells in vitro [8,14]. A prior study indicated that Cd exposure at 2.5–20 μM could induce excessive production of reactive oxygen species (ROS) and decrease the abilities of the antioxidant defense system, triggering oxidative stress damage and mitochondrial dysfunction in PC12 cells and rat primary cerebral cortical neurons [15]. Moreover, it was also documented that Cd exposure could also trigger the activation of p53, sirtuin-1 (SIRT1), mitogen-activated protein kinase (MAPK), PKR-like ER kinase (PERK)/activating transcription factor 4 (ATF4), and ferroptosis pathways in neuronal cells and human peripheral blood lymphocytes [13,15,16,17,18,19].
Ellagic acid (EA) is a polyphenolic compound (2,3,7,8-tetrahydroxychromeno (5,4,3-cde) chromene-5,10-dione, C14H6O8; Figure 1), and it could be found in multiple gallnuts and fruits, such as pomegranates, black currants, raspberries, and mangoes [20]. The literature reports that EA exhibits various biological activities, such as anti-inflammatory, antiviral, antioxidant, antimicrobial, and immune-regulatory effects [21]. A mouse model has demonstrated that oral EA administration could effectively attenuate rotenone exposure-induced dopamine neuronal damage via targeting activation of the Nrf2 pathway [22]. Goudarzi et al. study showed that oral EA supplementation at the doses of 10 and 30 mg/kg per day for successive twenty-one days can effectively attenuate sodium arsenate-caused neurotoxicity by inhibiting oxidative stress and neuroinflammation in the brain tissue of rats [23]. The current study aims to examine the protective effects of EA supplementation against Cd exposure-induced toxicity in HT22 cells, a mouse hippocampal neuronal cell line. Additionally, we explore the underlying molecular mechanisms.

2. Materials and Methods

2.1. Chemical and Reagents

Cadmium sulfate (CdSO4) (purity ≥ 98%) and ellagic acid (purity more than 96%) were both purchased from Aladdin (Shanghai, China). SB203580 (a special inhibitor of p38 MAPK), SP600125 (a special inhibitor of JNK), dimethyl sulfoxide (DMSO), 1% (v/v) penicillin-streptomycin, phenylmethanesulfonylfluoride (PMSF), pan-caspase inhibitor (Z-VAD-FMK), and N-acetylcysteine (NAC) were supplied by Beyotime Biotechnology Company (Haimen, Jiangsu, China). ASN007 (a special inhibitor of ERK) was purchased from MCE (Shanghai, China). Mito-TEMPO was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). All other chemical reagents used in the present study were at analysis grade.

2.2. Cell Viability and Treatment

The mouse HT22 and rat PC12 cell lines were both obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin-streptomycin under controlled conditions in a cell culture incubator (Thermo Fisher Scientific, Shanghai, China) maintained at 5% CO2 and 37 °C.

2.3. Measurement of Cell Viabilities

Cell viabilities were determined using a CCK-8 detection kit (Nanjing KeyGEN Biotech Co., Ltd., Nanjing, China), according to the instructions provided by the manufacturer. Briefly, A 96-well cell culture plate was used. A total of 1 × 104 cells were seeded per well. After 24 h cultivation, cells were treated with various concentrations of CdSO4 (0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) or EA (5, 10, 20, 40, and 80 μM) for another 24 h. After the treatment, cells were incubated with 10 μL of CCK-8 reagent for 1 h. Then, cell viabilities were determined at 450 nm using a microplate reader (Tecan Trading AG, Kanton Zürich, Switzerland).
We also tested the effects of EA, antioxidant NAC, and JNK inhibitor (i.e., SP600125) supplementation on Cd exposure-induced cytotoxicity in HT22 cells. In brief, cells were pre-treated with EA at the doses of 5, 10, and 20 μM, NAC at the dose of 2.5 mM, or the JNK inhibitor at a concentration of 10 μM, as well as SB203580 and ASN007 at concentrations of 5 and 10 μM for a duration of 2 h. Subsequently, the cells were co-treated with CdSO4 at a concentration of 10 μM for an additional 24 h. Finally, cell viability was assessed.

2.4. LDH Measurement

Shown in Supplementary Material and Methods.

2.5. Measurement of Cell Apoptosis

Cell apoptosis analysis was performed using a commercial Annexin V-FITC/PI Apoptosis Detection Kit (Vazyme Biotech Co., Ltd., Nanjing, China) by flow cytometry analysis (Becton Dickinson, San Jose, CA, USA), according to the description in a previous study [24]. Meanwhile, the nuclear morphological alterations were assessed using the Hoechst 33,342 staining technique. The aggregation of chromosomes and the formation of apoptotic bodies were identified as indicators of cell apoptosis and were quantified accordingly.

2.6. Measurement of Intracellular ROS Levels and Oxidative Stress Biomarkers

Shown in Supplementary Material and Methods.

2.7. Measurement of Mitochondrial ROS

The levels of mitochondrial ROS were measured using the MitoSOX staining method (M36008, Invitrogen, Shanghai, China), according to our previous study [25]. In brief, cells were pre-treated with EA at the dose of 20 μM or Mito-TEMPO at 5 μM for 2 h, then co-treated with or without CdSO4 at 10 μM for an additional 24 h. Then, cells were washed twice with PBS and incubated with MitoSOX Red (at 5 μM) plus 4′-6-diamidino-2-phenylindole (DAPI) for an additional 30 min. Finally, cells were washed using PBS twice, and a laser confocal microscope (Leica Microsystems, Hessen, Germany) was used to observe the changes in mitochondrial ROS.

2.8. Measurement of Intracellular ATP Levels

Show in Supplementary Material and Methods.

2.9. Western Blotting

The expression of proteins was analyzed using Western Blotting, according to the detailed protocol provided in a previous study [26]. Primary rabbit polyclonal antibodies targeting phosphorylated (p)-p38 (Thr180/Tyr182), p-JNK (Thr183/Tyr185), p-ERK1/2 (Thr202/Tyr204) (1:1000 dilution; CST company, Beverly, MA, USA), Nrf2, HO-1, Bax, Bcl-2, and caspase-3 (1:1000 dilution; Proteintech, Chicago, IL, USA), and mouse monoclonal antibody against β-actin (1:1000 dilution; Santa Cruz, CA, USA) were used. A detailed protocol is shown in the Supplementary Material and Methods.

2.10. qRT-PCR Analysis

The RNA samples were isolated using a commercial Fast Pure® Cell/Tissue Total RNA Isolation Kit V2 (Vazyme Biotech Co., Ltd.). The details are shown in Supplementary Material and Methods.

2.11. Statistical Analysis

All data were processed using GraphPad Prism 9.0 software. A nonlinear model-based approach from GraphPad Prism 9.0 software was employed for the calculation of IC50. All data were shown as means ± standard deviation (SD) unless specially stated. The differences between any two groups were performed under Tukey’s multiple comparison test of 1-way analysis of variance. A p-value < 0.05 was considered as considered statistically significant.

3. Results

3.1. EA Supplementation Attenuates CdSO4-Induced Loss of Cell Viability and the Release of LDH in HT22 Cells

We first established the toxic model of CdSO4 cytotoxicity in HT22 cells. The results showed that CdSO4 treatment for 24 h dose-dependently decreased cell viability in HT22 cells. As shown in Figure 2A, CdSO4 exposure at the concentrations of 2.5, 5, 10, 20, and 40 μM for 24 h reduced the cell viabilities to 86%, 77%, 65%, 33%, and 9% (all p < 0.01), respectively, and the half maximal inhibitory concentration (IC50) was 12.4 μM. Additionally, we also assessed the toxic effects of EA. As shown in Figure 2B, EA treatment at 5–20 μM for 24 h did not change the cell viabilities of HT22 cells, but at 40 and 80 μM, the cell viabilities were decreased to 85% and 61% (both p < 0.01), respectively, compared to the untreated cells. Therefore, the concentrations of EA at 5–20 μM in the following investigation were used. Then, EA treatment at 5–20 μM could effectively decrease CdSO4-induced cytotoxicity in HT22 cells, and it was in a dose-dependent manner. As shown in Figure 2C, EA treatment at concentrations of 5, 10, and 20 μM increased the cell viabilities to 77%, 84%, and 92% (all p < 0.01), respectively, compared to 10 μM CdSO4 group, increased the cell viabilities to 43%, 49%, and 59% (all p < 0.01), respectively, compared to 20 μM CdSO4 group; and increased cell viabilities to 20%, 26% (p < 0.01), and 29% (p < 0.01), respectively, compared to 40 μM CdSO4 group. Correspondingly, CdSO4 treatment at 10 μM for 24 h could result in marked morphology changes, such as cell shrinkage and lysis. EA co-treatment at 20 μM could improve these changes (Figure 2D). Similarly, in PC12 cells, CdSO4 exposure at 5 μM significantly decreased the cell viabilities to 56% (p < 0.01) and morphological changes, which were ameliorated by EA supplementation at the concentrations of 10 and 20 μM (Supplementary Figure S1). The corresponding cell viability increased to 66% and 74% (p < 0.05 or 0.01), respectively.
Additionally, a sub-IC50 concentration of CdSO4 at 10 μM was used to investigate the potential mechanisms of EA. The levels of LDH released by CdSO4 exposure and the protective effects of EA were assessed. Compared to the control group, CdSO4 exposure for 24 h could dose-dependently induce the release of LDH in the medium. The levels of LDH in the 2.5, 5, and 10 μM CdSO4 treatment groups were significantly increased to 2.2-, 3.7-, and 5.5-fold (all p < 0.01) (Figure 2E). Pre-treatment with EA at doses of 5, 10, and 20 μM significantly reduced LDH levels to 4.1-, 3.4-, and 1.7-fold (all p < 0.01), respectively, compared to the group treated with CdSO4 only (Figure 2F). Treatment with EA alone at a concentration of 20 μM for 24 h did not result in changes to the LDH levels of HT22 cells, compared to the untreated control group.

3.2. EA Supplementation Ameliorates CdSO4-Induced Cell Apoptosis in HT22 Cells

Exposure to CdSO4, when compared to the control group, resulted in significant changes in nuclear morphology. Figure 3A shows the presence of chromosomal aggregation and nuclear fragmentation in the 10 μM CdSO4 treatment group, effects that were effectively reversed by pre-treatment with EA. Similarly, EA pre-treatment at doses of 5, 10, and 20 μM markedly prevented Cd-induced cell apoptosis, leading to a decrease in apoptotic rates from 29% to 20%, 12%, and 8% (all p < 0.01) respectively, compared to that in the 10 μM CdSO4 only group (Figure 3B). Treatment with EA alone at a concentration of 20 μM for 24 h did not result in alterations in apoptotic rates in HT22 cells compared to those in the untreated control group. Consistently, our results also found that caspase pan-inhibitor Z-VAD-FMK treatment at the dose of 20 μM could markedly inhibit CdSO4-induced apoptosis (Supplementary Figure S2). These data suggested that apoptosis plays a critical role in CdSO4-induced cell death and the protective effects of EA.
Similarly, we also found that Cd exposure at 5 μM increased the apoptosis rates to 43% (p < 0.01) compared to the control group. EA supplementation at 5, 10, and 20 μM decreased the apoptosis rates to 34%, 23%, and 17% (all p < 0.01), respectively (Supplementary Figure S3). EA supplementation at 20 μM for 24 h did not affect the apoptosis rates in PC12 cells compared to the untreated control group (Supplementary Figure S3).

3.3. EA Supplementation Attenuates CdSO4-Induced ROS Production and Oxidative Stress Damage in HT22 Cells

Supplementary Figure S4A shows that the fluorescence intensities of DCFH-DA in HT22 cells treated with CdSO4 alone were significantly heightened. This effect was partially alleviated by co-treatment with EA in a dose-dependent manner. A similar finding was also detected in PC12 cells (Supplementary Figure S4B). Then, the quantitative analysis using flow cytometry revealed a notable increase in fluorescence intensities to 46% in the 10 μM CdSO4 treatment group in HT22 cells. Meanwhile, EA treatment at concentrations of 5, 10, and 20 μM led to significant reductions in fluorescence intensities to 30%, 26%, and 14% (all p < 0.01), respectively, compared to the group solely treated with CdSO4 (Figure 4A). Furthermore, the MitoSOX staining was performed. The results showed that the mitochondrial ROS levels were significantly increased to 2.6-fold, which were effectively decreased to 1.3- and 1.1-fold (both p < 0.01) by EA (at 20 μM) and Mito-TEMPO (at 5 μM) (Figure 4B). Antioxidant N-acetylcysteine (NAC) supplementation (at 2.5 mM) could effectively mitigate CdSO4-induced ROS production (Figure 4C) and partially alleviated CdSO4-induced cytotoxicity, resulting in an increase in the cell viability from 61% to 90% (p < 0.01; Figure 4D).
Additionally, the oxidative stress biomarkers, including MDA levels and the activities of SOD and CAT in HT22 cells, were evaluated. The results demonstrated that supplementation with EA effectively ameliorated Cd-induced oxidative damage. In Figure 4B–D, compared to the group exposed to 10 μM CdSO4 only, treatment with EA at concentrations of 5, 10 and 20 μM notably reduced MDA levels from 0.85 nmol/mg protein to 0.65, 0.60 and 0.39 nmol/mg protein (all p < 0.01), respectively. Moreover, EA treatment significantly increased CAT activities from 2.1 U/mg protein to 3.3, 4.5 and 5.1 U/mg protein (all p < 0.05 or 0.01), respectively, and elevated SOD activities from 24.2 U/mg protein increased to 35.2, 41.3 and 51.5 U/mg protein (all p < 0.05 or 0.01). Notably, EA treatment at the concentration of 20 μM did not alter the levels of MDA or the activities of CAT and SOD compared to the control group (Figure 4E–G).

3.4. EA Supplementation Attenuates CdSO4-Caused Mitochondrial Dysfunction

Mitochondrial function was evaluated by measuring changes in mitochondrial membrane potential. In Figure 5A, EA treatment at concentrations of 5, 10, and 20 μM significantly increased the membrane potential from 56% to 70%, 81%, and 93% (all p < 0.05 or 0.01), respectively, compared to the group exposed to CdSO4 alone. Consistently, NAC supplementation significantly attenuated the loss of mitochondrial membrane potential induced by CdSO4 exposure (Supplementary Figure S5). Consistently, we also found that CdSO4 exposure significantly decreased the intracellular ATP levels to 46% (p < 0.01), and EA supplementation at 10 and 20 μM effectively restored the intracellular ATP levels to 89% and 92% (both p < 0.01) (Figure 5B). Additionally, EA treatment at a dose of 20 μM did not alter the mitochondrial membrane potential and the intracellular ATP levels compared to the untreated control group (Figure 5).

3.5. EA Supplementation Upregulates the Expression of Nrf2, HO-1, and Bcl-2 Proteins and Downregulates the Expression of Bax, p-JNK, p-p38, and p-ERK Proteins

Compared to the untreated control group, exposure to 10 μM CdSO4 significantly upregulated the expression of Nrf2, HO-1, p-Erk1/2, p-JNK, p-p38, Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins by 1.9-, 10.1-, 2.4-, 4.3-, 3.7-, 1.9-, 4.0- and 2.6-fold, respectively (all p < 0.01) (Figure 6). These protein expressions were modulated by EA supplementation. EA supplementation at a dose of 20 μM plus CdSO4 treatment significantly increased the expression of Nrf2 and HO-1 proteins by 3.1- and 16.3-fold, respectively, while notably decreasing the expression of p-Erk1/2, p-JNK, p-p38, Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins to 1.5-, 2.0-, 1.6-, 1.2-, 2.1-, and 1.0-fold (all p < 0.01; Figure 6), respectively. Furthermore, we also found that EA supplementation could significantly upregulate the expression of Nrf2, HO-1, and Bcl-2 mRNAs and significantly downregulate the expression of Bax mRNA. As shown in Supplementary Figure S6, EA supplementation at 20 µM significantly upregulated the expression of Nrf2 mRNA from 1.9-fold to 3.6-fold, upregulated the expression of HO-1 from 4.6-fold to 10.1-fold, upregulated the expression of Bcl-2 from 0.4-fold to 0.9-fold, and significantly downregulated the expression of Bax from 2.3-fold to 1.2-fold, compared to those in the CdSO4-only group. EA alone treatment at 20 µM upregulated the expression of Nrf2 and HO-1 mRNAs but did not affect the expression of Bcl-2 and Bax mRNAs compared to those in the control group (Supplementary Figure S6).
We also confirmed the impact of oxidative stress on CdSO4-induced activation of the JNK and mitochondrial apoptotic pathways. As shown in Supplementary Figure S7, NAC supplementation led to a substantial decrease in the expression of p-JNK, the Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins. In the NAC and CdSO4 co-treatment group, the levels of p-JNK, the Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins nearly normalized, and they were decreased to 1.3-, 0.8-, 1.1-, and 1.1-fold (all p < 0.01) (Supplementary Figure S7), respectively. When compared to the control group, treatment with NAC alone did not affect the expression of the aforementioned proteins (Supplementary Figure S7).

3.6. The Pharmacological Inhibition of JNK Promotes CdSO4-Induced Cytotoxicity

We further investigated the impact of the MAPK pathway on CdSO4 exposure-induced cytotoxicity. We found that pharmacological inhibitions of p38 and ERK pathways by SB203580 and ASN007 did not affect CdSO4-induced cytotoxicity in HT22 cells (Supplementary Figure S8). However, the pharmacological inhibition of JNK by SP600125 could significantly exacerbate CdSO4 exposure-induced cytotoxicity (Figure 7A). Additionally, JNK inhibition led to a substantial decrease in the expression of Nrf2 and HO-1 proteins, which were decreased to 1.1- and 5.2-fold (both p < 0.05), respectively. On the contrary, compared to the group exposed to CdSO4 only, JNK inhibition significantly increased the expression of the Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins to 2.4-fold (p < 0.05), 4.3- fold (p < 0.01), and 3.8-fold (p < 0.05) (Figure 7B).

4. Discussion

Neurotoxicity is one of the multiple toxic effects caused by CdSO4 exposure [18]. Previous studies demonstrated that CdSO4 exposure at the range of 0.625–20 μM could induce marked decreases in the cell viability in PC12 cells and HT22 cells [13,27]. Consistent with a previous study [13], our current study reveals that exposure to CdSO4 at concentrations ranging from 0.625 to 40 μM resulted in dose-dependent cell death in HT22 cells. Previous studies have reported that the different test methods have different sensitivity to Cd-induced cytotoxicity [28]. One non-negligible reason is that some heavy metals can affect the sensitivity of CCK-8 detection, and it might be increased with the increase of heavy metal concentration. In the present study, we used two methods, i.e., the CCK-8 and LDH methods, to assess the cytotoxicity and the protective effects of EA. Our results found that the LDH method is more sensitive than the CCK-8 method in Cd-treated HT22 cells (Figure 2). Meanwhile, we found that both two methods demonstrated the protective effects of EA on Cd-induced cytotoxicity (Figure 2). Similarly, EA supplementation at 5–20 μM could provide protection against Cd-induced cytotoxicity in PC12 cells (Supplementary Figure S1). Furthermore, we observed a dose-dependent inhibition by EA supplementation on CdSO4 exposure-induced oxidative stress, cell apoptosis, and mitochondrial dysfunction. These effects may be linked to EA’s ability to scavenge free radicals, enhance antioxidant defense function, inhibit the JNK pathway, and activate the Nrf2/HO-1 pathway (Figure 3, Figure 4, Figure 5, Figure 6, Figure 7 and Supplementary Figures S2–S8).
Apoptosis, a form of programmed cell death, can be induced by various drugs or environmental toxins, such as copper, cisplatin, and T-2 toxin [26,29,30,31]. In this study, we observed that exposure to CdSO4 could initiate cell apoptosis (Figure 3), consistent with prior research [32,33]. Furthermore, our findings revealed that EA supplementation effectively ameliorated CdSO4-induced cell apoptosis in HT22 and PC12 cells (Figure 3 and Supplementary Figures S2 and S3). Several previous studies demonstrated that EA supplementation can reduce drugs or toxins-induced apoptotic cell death in vitro and in vivo [34,35,36]. These findings suggest that EA’s protective effects against CdSO4-induced cytotoxicity involve the inhibition of apoptosis.
Apoptotic cell death could be triggered by multiple signals, including ROS, p53, and other apoptosis-related factors [26,37]. A prior study demonstrated that exposure to CdSO4 can induce excessive ROS production, leading to direct damage to intracellular macromolecules (such as DNA, lipids, and proteins) and subcellular organelles (such as mitochondria, endoplasmic reticulum, and lysosomes), ultimately culminating in cell apoptosis [38]. Our current findings reveal that CdSO4 exposure significantly elevates intracellular ROS in HT22 cells and PC12 cells (Figure 4 and Supplementary Figure S4). Meanwhile, CdSO4 exposure significantly upregulated the MDA levels while simultaneously decreasing the activities of SOD and CAT in HT22 cells (Figure 4). We also found that CdSO4 exposure could significantly upregulate the mitochondrial ROS levels (Figure 4). Similarly, Hyun et al. showed that Cd exposure at 10–40 μM for 24 h could significantly upregulate the mitochondrial ROS levels in human prostate stromal cells and mouse embryonic fibroblasts [39]. These data suggested that CdSO4 exposure-induced excessive production is partly dependent on the production of mitochondrial ROS. SOD and CAT, as antioxidant enzymes, play crucial roles in combating oxidative stress by scavenging intracellular superoxide and hydroxyl radicals [26]. Increased MDA levels serve as an essential indicator of membrane lipid peroxidation [25]. These results indicate that CdSO4 exposure elicits oxidative stress damage in HT22 cells. Notably, EA supplementation effectively attenuates CdSO4-induced ROS and mitochondrial ROS productions and enhances SOD and CAT activities (Figure 4). Previous studies by Firdaus et al. demonstrated that EA pre-treatment at 10–20 μM can inhibit ROS production and apoptosis induced by arsenic trioxide in human neuroblastoma SH-SY5Y cells [40]. Similarly, Ding et al. reported that EA treatment at 15–30 μM reduces ROS production and MDA levels caused by high glucose exposure while improving SOD activities in HepG2 cells [41]. Moreover, Zhao et al. showed that EA supplementation at doses of 50–100 mg/kg/day for four weeks upregulates antioxidant enzymes, including CAT, SOD, and GSH-PX, to ameliorate ethanol exposure-induced liver injury in a mouse model [42]. Collectively, these findings suggest that EA supplementation effectively reduces CdSO4-induced apoptosis by alleviating oxidative stress and mitochondrial ROS production. Furthermore, our study found that ATP production was significantly decreased after CdSO4 exposure, indicating mitochondrial dysfunction (Figure 5). It is known that mitochondrial respiration mainly relies on the enzymatic activities of five mitochondrial complexes that couple electron transport with proton pumping, finally leading to ATP synthesis [43]. Several previous studies also reported that Cd is a potent uncoupling agent and can inhibit mitochondrial respiratory chain activities by interacting with CI at the Q site and NADH site and complexes I (CI), CII, and CIII at the Fe–S cluster [14,44,45,46]. Our results also showed that EA treatment for 24 h could effectively restore CdSO4 exposure-induced loss of intracellular ATP (Figure 5). These data suggested that EA supplementation may provide protection for CdSO4 exposure-induced mitochondrial dysfunction via the inhibition of oxidative stress. The inhibition of complexes I and II could induce ROS generation [47,48]. Khodaei et al.’s findings showed that EA supplementation could inhibit cuprizone exposure-induced loss of CII, CIII, and CIV proteins in mouse muscle tissue [49]. Therefore, the regulation of EA on mitochondrial complexes may participate in its protective effects against CdSO4-induced mitochondrial dysfunction. This is a limitation of our current study. Further investigation is warranted to elucidate the underlying molecular mechanisms.
Mitochondria serve not only as producers but also as targets of ROS [50]. Bax, a pro-apoptotic protein, contrasts with Bcl-2, an anti-apoptotic protein [50]. The mitochondrial membrane potential assessment stands as a pivotal indicator of mitochondrial dysfunction [26]. Deng et al. observed a significant loss of mitochondrial membrane potential in N2a neuronal cells upon exposure to cadmium chloride (CdCl2) [1]. The elevation in the Bax/Bcl-2 ratio can instigate mitochondrial dysfunction, triggering the release of CytC and subsequently activating caspases-9 and -3 in a cascading fashion, culminating in cell apoptosis [51]. Poly (ADP-ribose) polymerase-1 (PARP-1) acts as a target of activated caspases-3 in caspase-dependent apoptosis, with cleaved PARP-1 suppressing DNA repair and serving as a key marker of apoptosis [52]. Our study demonstrates that CdSO4 exposure notably diminishes mitochondrial membrane potential, leading to an increase in the Bax/Bcl-2 ratio, ultimately resulting in the upregulation of cleaved caspase-3 and cleaved PARP-1 protein expression (Figure 5 and Figure 6 and Supplementary Figure S6). Pan-caspase inhibitors could markedly revise CdSO4-induced cell apoptosis (Supplementary Figure S2), indicating that CdSO4-induced apoptotic cell death is caspase-dependent. EA supplementation partially reduces these CdSO4-induced alterations (Figure 5 and Figure 6 and Supplementary Figure S6). Furthermore, our data reveals that the antioxidant NAC supplementation significantly attenuates CdSO4-induced cytotoxicity by suppressing ROS production and the mitochondrial apoptotic pathway (Figure 4 and Supplementary Figures S5 and S7). Therefore, these findings suggest that EA supplementation could effectively safeguard against CdSO4-induced apoptosis by hindering mitochondrial dysfunction and the mitochondrial apoptotic pathway in HT22 cells, potentially attributable to its role in oxidative stress modulation.
Nrf2, a crucial transcription factor often referred to as a “housekeeper,” responds to oxidative stress and inflammatory damage [53,54]. Studies have highlighted that Nrf2 activation exerts a protective effect against Cd-induced cytotoxicity and tissue damage [55,56]. Consistent with prior findings, our study demonstrated a significant upregulation of Nrf2 mRNA and protein expression and its downstream gene HO-1 following CdSO4 exposure, with further enhancements observed upon co-treatment with EA (Figure 6 and Supplementary Figure S6). Recent research has underscored Nrf2 as a vital target of EA, showing that EA promotes nuclear Nrf2 expression by inhibiting Keap1 expression [57]. Notably, Nrf2 knockout partially attenuated the protective effects of EA against rotenone-induced neurotoxicity in a mouse model [22]. Our current data strongly suggest that Nrf2 activation contributes to the EA-mediated protection against CdSO4-induced apoptosis.
Previous studies have shown that Cd exposure can promptly activate the MAPK pathway, leading to a significant upregulation of p-Erk1/2, p-JNK, and p-p38 proteins in various cell types, including PC12 and SH-SY5Y neuronal cells and human bronchial epithelial cells (BEAS-2B) [58,59,60]. In these cell models, researchers observed that the inhibition of p-Erk1/2 and p-JNK partially attenuated Cd exposure-induced cell apoptosis [58,59,60]. Conversely, Liu et al. reported that inhibiting JNK did not influence Cd exposure-induced cell death in BmE cells, a silkworm embryonic cell line [61]. Given its diverse functions, the MAPK pathway typically exhibits a dual role in regulating cell apoptosis [62]. For instance, Hu et al. demonstrated that JNK-mediated activation of the Nrf2 pathway contributed to the protective effects of coptisine against 2,2′-azodiisobutyramidine dihydrochloride-induced oxidative stress damage in zebrafish embryos [62]. In the present study, we observed that JNK inhibition, not p38 and ERK inhibition, could promote CdSO4-induced cytotoxicity at 24 h (Supplementary Figure S8). Moreover, JNK inhibition by SP600125 markedly suppresses the expression of Nrf2 and HO-1 proteins, consequently exacerbating the mitochondrial apoptotic pathway and ultimately exacerbating CdSO4 exposure-induced cell death (Figure 7). We also found that blocking oxidative stress with NAC substantially inhibited JNK activation (Supplementary Figure S7), suggesting that oxidative stress is a crucial upstream regulator of the JNK pathway in CdSO4-induced cytotoxicity. For the MAPK pathway, the time profile of activation is usually responsible for the biological outcome. In the current study, we just tested the effects of the MAPK pathway on CdSO4-induced cytotoxicity at 24 h. The dynamic changes of the MAPK pathway in response to CdSO4 and how it mediates the protective effects of EA are still unknown. This is another limitation of the present study.
Importantly, EA has a higher safety for humans and animals and has been used in food production as a food additive [63,64]. Tasaki et al. found that the no-observed-effect levels (via the 90-day sub-chronic toxicity study) of EA in male or female rats are 3011 mg/kg body weight/day and 3254 mg/kg body weight/day, respectively [63]. Various studies indicate that oral EA supplementation at 10–100 mg/kg body weight per day could provide neuroprotection for drugs or environmental toxins (such as rotenone, 6-hydroxydopamine, and 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine)-induced neurotoxicity in rats or mice [22,36,65,66]. A recent human trial showed that EA intervention (90 mg twice a day for 12 weeks) could provide a favorable effect on depression in multiple sclerosis [67]. The information indicated that oral supplementation of EA is safer. Taken together, these findings suggest that EA may be a potential protective agent against Cd-induced neurotoxicity, and further commercial development could be considered.

5. Conclusions

In summary, our results demonstrate that EA supplementation effectively reduced CdSO4-induced cytotoxicity in HT22 cells by inhibiting oxidative stress and apoptosis, potentially via the activation of the Nrf2/HO-1 pathway. Additionally, the activation of the JNK pathway in response to CdSO4 exposure also confers protection via the Nrf2/HO-1 pathway. A proposed model illustrating the impact of EA supplementation on CdSO4-induced apoptosis is presented in Figure 8. This study highlights EA as a promising candidate for combating Cd-induced cytotoxicity and neurotoxicity.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antiox13111296/s1, Supplementary Figure S1 The morphology changes (left) and the results of cell viabilities (right) in PC12 cells after CdSO4 treatment with or without ellagic acid (EA). Supplementary Figure S2 Pan-caspase inhibitor Z-VAD-FMK suppresses CdSO4-induced apoptosis in HT22 cells. Supplementary Figure S3 Ellagic acid (EA) supplementation attenuates CdSO4-induced cell apoptosis in PC12 cells. Supplementary Figure S4 Representative images of DCFH-DA staining in HT22 cells (A) and PC12 cells (B). Supplementary Figure S5 NAC supplementation attenuates CdSO4-induced alterations in mitochondrial membrane potential. Supplementary Figure S6 The mRNA expression of Nrf2 (A), HO-1 (B), Bcl-2 (C), and Bax (D) genes. Supplementary Figure S7 NAC supplementation attenuates CdSO4-induced activation of JNK and mitochondrial apoptotic pathways. Supplementary Figure S8 Effects of pharmacological inhibition of p38 (A) and Erk (B) pathways by SB203580 and ASN007 on CdSO4 exposure-induced cytotoxicity. References [24,26] are cited in the supplementary materials.

Author Contributions

Investigation, Y.L. and C.C.; data curation, Y.L., C.C. and Z.H.; writing—original draft preparation, Y.L., C.C., and C.D.; methodology, Y.L., C.D. and S.T.; formal analysis, Y.L., C.D. and S.T.; validation, Y.L., C.D. and S.T.; writing—review and editing, C.D. and J.S.; supervision, C.D. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded and supported by the Guangdong Major Project of Basic and Applied Basic Research (2020B0301030007). It was funded by the National Natural Science Foundation of China (Award number 32102724) and the Pinduoduo-China Agricultural University Research Fund (Grant No. PC2023A01002).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are contained within the article and Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Deng, P.; Zhang, H.; Wang, L.; Jie, S.; Zhao, Q.; Chen, F.; Yue, Y.; Wang, H.; Tian, L.; Xie, J.; et al. Long-term cadmium exposure impairs cognitive function by activating lnc-Gm10532/m6A/FIS1 axis-mediated mitochondrial fission and dysfunction. Sci. Total Environ. 2023, 858, 159950. [Google Scholar] [CrossRef]
  2. Wang, M.; Chen, Z.; Song, W.; Hong, D.; Huang, L.; Li, Y. A review on Cadmium Exposure in the Population and Intervention Strategies Against Cadmium Toxicity. Bull. Environ. Contam. Toxicol. 2021, 106, 65–74. [Google Scholar] [CrossRef]
  3. Tinkov, A.A.; Gritsenko, V.A.; Skalnaya, M.G.; Cherkasov, S.V.; Aaseth, J.; Skalny, A.V. Gut as a target for cadmium toxicity. Environ. Pollut. 2018, 235, 429–434. [Google Scholar] [CrossRef]
  4. Xie, D.; Yan, J.; Zhang, H.; Zhang, H.; Nie, G.; Zhu, X.; Li, X. Cadmium exacerbates liver injury by remodeling ceramide metabolism: Multiomics and laboratory evidence. Sci. Total Environ. 2024, 923, 171405. [Google Scholar] [CrossRef]
  5. Zhao, C.; Yu, D.; He, Z.; Bao, L.; Feng, L.; Chen, L.; Liu, Z.; Hu, X.; Zhang, N.; Wang, T.; et al. Endoplasmic reticulum stress-mediated autophagy activation is involved in cadmium-induced ferroptosis of renal tubular epithelial cells. Free Radic. Biol. Med. 2021, 175, 236–248. [Google Scholar] [CrossRef]
  6. Qu, Z.; Liu, L.; Wu, X.; Guo, P.; Yu, Z.; Wang, P.; Song, Y.; Zheng, S.; Liu, N. Cadmium-induced reproductive toxicity combined with a correlation to the oogenesis process and competing endogenous RNA networks based on a Caenorhabditis elegans model. Ecotoxicol. Environ. Saf. 2023, 268, 115687. [Google Scholar] [CrossRef]
  7. Wang, Z.; Sun, Y.; Yao, W.; Ba, Q.; Wang, H. Effects of Cadmium Exposure on the Immune System and Immunoregulation. Front. Immunol. 2021, 12, 695484. [Google Scholar] [CrossRef]
  8. Min, J.Y.; Min, K.B. Blood cadmium levels and Alzheimer’s disease mortality risk in older US adults. Environ. Health 2016, 15, 69. [Google Scholar] [CrossRef]
  9. Bakulski, K.M.; Seo, Y.A.; Hickman, R.C.; Brandt, D.; Vadari, H.S.; Hu, H.; Park, S.K. Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias. J. Alzheimer’s Dis. 2020, 76, 1215–1242. [Google Scholar] [CrossRef]
  10. Xu, L.; Zhang, W.; Liu, X.; Zhang, C.; Wang, P.; Zhao, X. Circulatory Levels of Toxic Metals (Aluminum, Cadmium, Mercury, Lead) in Patients with Alzheimer’s Disease: A Quantitative Meta-Analysis and Systematic Review. J. Alzheimer’s Dis. 2018, 62, 361–372. [Google Scholar] [CrossRef]
  11. Wang, H.; Abel, G.M.; Storm, D.R.; Xia, Z. Adolescent cadmium exposure impairs cognition and hippocampal neurogenesis in C57BL/6 mice. Environ. Toxicol. 2022, 37, 335–348. [Google Scholar] [CrossRef]
  12. Wang, H.; Zhang, L.; Abel, G.M.; Storm, D.R.; Xia, Z. Cadmium Exposure Impairs Cognition and Olfactory Memory in Male C57BL/6 Mice. Toxicol. Sci. Off. J. Soc. Toxicol. 2018, 161, 87–102. [Google Scholar] [CrossRef]
  13. Wang, D.; Wu, Y.; Zhou, X.; Liang, C.; Ma, Y.; Yuan, Q.; Wu, Z.; Hao, X.; Zhu, X.; Li, X.; et al. Cadmium exposure induced neuronal ferroptosis and cognitive deficits via the mtROS-ferritinophagy pathway. Environ. Pollut. 2024, 349, 123958. [Google Scholar] [CrossRef]
  14. Branca, J.J.V.; Pacini, A.; Gulisano, M.; Taddei, N.; Fiorillo, C.; Becatti, M. Cadmium-Induced Cytotoxicity: Effects on Mitochondrial Electron Transport Chain. Front. Cell Dev. Biol. 2020, 8, 604377. [Google Scholar] [CrossRef]
  15. Wen, S.; Xu, M.; Zhang, W.; Song, R.; Zou, H.; Gu, J.; Liu, X.; Bian, J.; Liu, Z.; Yuan, Y. Cadmium induces mitochondrial dysfunction via SIRT1 suppression-mediated oxidative stress in neuronal cells. Environ. Toxicol. 2023, 38, 743–753. [Google Scholar] [CrossRef]
  16. Khan, A.; Ikram, M.; Muhammad, T.; Park, J.; Kim, M.O. Caffeine Modulates Cadmium-Induced Oxidative Stress, Neuroinflammation, and Cognitive Impairments by Regulating Nrf-2/HO-1 In Vivo and In Vitro. J. Clin. Med. 2019, 8, 680. [Google Scholar] [CrossRef]
  17. Chandler, J.D.; Wongtrakool, C.; Banton, S.A.; Li, S.; Orr, M.L.; Barr, D.B.; Neujahr, D.C.; Sutliff, R.L.; Go, Y.M.; Jones, D.P. Low-dose oral cadmium increases airway reactivity and lung neuronal gene expression in mice. Physiol. Rep. 2016, 4, e12821. [Google Scholar] [CrossRef]
  18. Al Olayan, E.M.; Aloufi, A.S.; AlAmri, O.D.; El-Habit, O.H.; Abdel Moneim, A.E. Protocatechuic acid mitigates cadmium-induced neurotoxicity in rats: Role of oxidative stress, inflammation and apoptosis. Sci. Total Environ. 2020, 723, 137969. [Google Scholar] [CrossRef]
  19. Al-Assaf, A.H.; Alqahtani, A.M.; Alshatwi, A.A.; Syed, N.A.; Shafi, G.; Hasan, T.N. Mechanism of cadmium induced apoptosis in human peripheral blood lymphocytes: The role of p53, Fas and Caspase-3. Environ. Toxicol. Pharmacol. 2013, 36, 1033–1039. [Google Scholar] [CrossRef]
  20. Kim, D.H.; Sim, Y.; Hwang, J.H.; Kwun, I.S.; Lim, J.H.; Kim, J.; Kim, J.I.; Baek, M.C.; Akbar, M.; Seo, W.; et al. Ellagic Acid Prevents Binge Alcohol-Induced Leaky Gut and Liver Injury through Inhibiting Gut Dysbiosis and Oxidative Stress. Antioxidants 2021, 10, 1386. [Google Scholar] [CrossRef]
  21. Gupta, A.; Singh, A.K.; Kumar, R.; Jamieson, S.; Pandey, A.K.; Bishayee, A. Neuroprotective Potential of Ellagic Acid: A Critical Review. Adv. Nutr. 2021, 12, 1211–1238. [Google Scholar] [CrossRef]
  22. Wei, Y.Z.; Zhu, G.F.; Zheng, C.Q.; Li, J.J.; Sheng, S.; Li, D.D.; Wang, G.Q.; Zhang, F. Ellagic acid protects dopamine neurons from rotenone-induced neurotoxicity via activation of Nrf2 signalling. J. Cell Mol. Med. 2020, 24, 9446–9456. [Google Scholar] [CrossRef]
  23. Goudarzi, M.; Amiri, S.; Nesari, A.; Hosseinzadeh, A.; Mansouri, E.; Mehrzadi, S. The possible neuroprotective effect of ellagic acid on sodium arsenate-induced neurotoxicity in rats. Life Sci. 2018, 198, 38–45. [Google Scholar] [CrossRef]
  24. Dai, C.; Ciccotosto, G.D.; Cappai, R.; Tang, S.; Li, D.; Xie, S.; Xiao, X.; Velkov, T. Curcumin Attenuates Colistin-Induced Neurotoxicity in N2a Cells via Anti-inflammatory Activity, Suppression of Oxidative Stress, and Apoptosis. Mol. Neurobiol. 2018, 55, 421–434. [Google Scholar] [CrossRef]
  25. Dai, C.; Li, M.; Sun, T.; Zhang, Y.; Wang, Y.; Shen, Z.; Velkov, T.; Tang, S.; Shen, J. Colistin-induced pulmonary toxicity involves the activation of NOX4/TGF-β/mtROS pathway and the inhibition of Akt/mTOR pathway. Food Chem. Toxicol. 2022, 163, 112966. [Google Scholar] [CrossRef]
  26. Li, M.; Tang, S.; Velkov, T.; Shen, J.; Dai, C. Copper exposure induces mitochondrial dysfunction and hepatotoxicity via the induction of oxidative stress and PERK/ATF4 -mediated endoplasmic reticulum stress. Environ. Pollut. 2024, 352, 124145. [Google Scholar] [CrossRef]
  27. Ben, P.; Zhang, Z.; Xuan, C.; Sun, S.; Shen, L.; Gao, Y.; Cao, X.; Zhou, Y.; Lan, L.; Yin, Z.; et al. Protective Effect of L-Theanine on Cadmium-Induced Apoptosis in PC12 Cells by Inhibiting the Mitochondria-Mediated Pathway. Neurochem. Res. 2015, 40, 1661–1670. [Google Scholar] [CrossRef]
  28. Fotakis, G.; Timbrell, J.A. In vitro cytotoxicity assays: Comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol. Lett. 2006, 160, 171–177. [Google Scholar] [CrossRef]
  29. Chen, J.; Chu, Y.; Cao, J.; Yang, Z.; Guo, X.; Wang, Z. T-2 toxin induces apoptosis, and selenium partly blocks, T-2 toxin induced apoptosis in chondrocytes through modulation of the Bax/Bcl-2 ratio. Food Chem. Toxicol. 2006, 44, 567–573. [Google Scholar] [CrossRef]
  30. Liu, J.; Wang, L.; Guo, X.; Pang, Q.; Wu, S.; Wu, C.; Xu, P.; Bai, Y. The role of mitochondria in T-2 toxin-induced human chondrocytes apoptosis. PLoS ONE 2014, 9, e108394. [Google Scholar] [CrossRef]
  31. Mokhtari, Z.; Seyedhashemi, E.; Eftekhari, M.; Ghasemi, S.; Sabouri, A.; Abbaszadeh-Goudarzi, K.; Abuali, M.; Azimi, H.; Kesharwani, P.; Pourghadamyari, H.; et al. Enhancement of cisplatin-induced apoptosis by saffron in human lung cancer cells. J. Trace Elem. Med. Biol. 2023, 79, 127229. [Google Scholar] [CrossRef] [PubMed]
  32. Wang, T.; Yan, L.; Wang, L.; Sun, J.; Qu, H.; Ma, Y.; Song, R.; Tong, X.; Zhu, J.; Yuan, Y.; et al. VPS41-mediated incomplete autophagy aggravates cadmium-induced apoptosis in mouse hepatocytes. J. Hazard. Mater. 2023, 459, 132243. [Google Scholar] [CrossRef] [PubMed]
  33. Yi, L.; Shang, X.J.; Lv, L.; Wang, Y.; Zhang, J.; Quan, C.; Shi, Y.; Liu, Y.; Zhang, L. Cadmium-induced apoptosis of Leydig cells is mediated by excessive mitochondrial fission and inhibition of mitophagy. Cell Death Dis. 2022, 13, 928. [Google Scholar] [CrossRef]
  34. Arab, H.H.; Gad, A.M.; Fikry, E.M.; Eid, A.H. Ellagic acid attenuates testicular disruption in rheumatoid arthritis via targeting inflammatory signals, oxidative perturbations and apoptosis. Life Sci. 2019, 239, 117012. [Google Scholar] [CrossRef]
  35. Aslan, A.; Hussein, Y.T.; Gok, O.; Beyaz, S.; Erman, O.; Baspinar, S. Ellagic acid ameliorates lung damage in rats via modulating antioxidant activities, inhibitory effects on inflammatory mediators and apoptosis-inducing activities. Environ. Sci. Pollut. Res. Int. 2020, 27, 7526–7537. [Google Scholar] [CrossRef] [PubMed]
  36. Ardah, M.T.; Eid, N.; Kitada, T.; Haque, M.E. Ellagic Acid Prevents α-Synuclein Aggregation and Protects SH-SY5Y Cells from Aggregated α-Synuclein-Induced Toxicity via Suppression of Apoptosis and Activation of Autophagy. Int. J. Mol. Sci. 2021, 22, 13398. [Google Scholar] [CrossRef]
  37. Dai, C.; Li, J.; Tang, S.; Li, J.; Xiao, X. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob. Agents Chemother. 2014, 58, 4075–4085. [Google Scholar] [CrossRef]
  38. Luo, H.; Gu, R.; Ouyang, H.; Wang, L.; Shi, S.; Ji, Y.; Bao, B.; Liao, G.; Xu, B. Cadmium exposure induces osteoporosis through cellular senescence, associated with activation of NF-κB pathway and mitochondrial dysfunction. Environ. Pollut. 2021, 290, 118043. [Google Scholar] [CrossRef]
  39. Hyun, M.; Kim, H.; Kim, J.; Lee, J.; Lee, H.J.; Rathor, L.; Meier, J.; Larner, A.; Lee, S.M.; Moon, Y.; et al. Melatonin protects against cadmium-induced oxidative stress via mitochondrial STAT3 signaling in human prostate stromal cells. Commun. Biol. 2023, 6, 157. [Google Scholar] [CrossRef]
  40. Firdaus, F.; Zafeer, M.F.; Waseem, M.; Anis, E.; Hossain, M.M.; Afzal, M. Ellagic acid mitigates arsenic-trioxide-induced mitochondrial dysfunction and cytotoxicity in SH-SY5Y cells. J. Biochem. Mol. Toxicol. 2018, 32, e22024. [Google Scholar] [CrossRef]
  41. Ding, X.; Jian, T.; Wu, Y.; Zuo, Y.; Li, J.; Lv, H.; Ma, L.; Ren, B.; Zhao, L.; Li, W.; et al. Ellagic acid ameliorates oxidative stress and insulin resistance in high glucose-treated HepG2 cells via miR-223/keap1-Nrf2 pathway. Biomed. Pharmacother. 2019, 110, 85–94. [Google Scholar] [CrossRef] [PubMed]
  42. Zhao, L.; Mehmood, A.; Soliman, M.M.; Iftikhar, A.; Iftikhar, M.; Aboelenin, S.M.; Wang, C. Protective Effects of Ellagic Acid Against Alcoholic Liver Disease in Mice. Front. Nutr. 2021, 8, 744520. [Google Scholar] [CrossRef]
  43. Vercellino, I.; Sazanov, L.A. The assembly, regulation and function of the mitochondrial respiratory chain. Nat. Rev. Mol. Cell Biol. 2022, 23, 141–161. [Google Scholar] [CrossRef]
  44. Wolin, M.S. Evidence for novel aspects of Nox4 oxidase regulation of mitochondrial function and peroxide generation in an endothelial cell model of senescence. Biochem. J. 2013, 452, e1–e2. [Google Scholar] [CrossRef] [PubMed]
  45. Okoye, C.N.; MacDonald-Jay, N.; Kamunde, C. Effects of bioenergetics, temperature and cadmium on liver mitochondria reactive oxygen species production and consumption. Aquat. Toxicol. 2019, 214, 105264. [Google Scholar] [CrossRef]
  46. Adiele, R.C.; Stevens, D.; Kamunde, C. Differential inhibition of electron transport chain enzyme complexes by cadmium and calcium in isolated rainbow trout (Oncorhynchus mykiss) hepatic mitochondria. Toxicol. Sci. Off. J. Soc. Toxicol. 2012, 127, 110–119. [Google Scholar] [CrossRef] [PubMed]
  47. Okoye, C.N.; Koren, S.A.; Wojtovich, A.P. Mitochondrial complex I ROS production and redox signaling in hypoxia. Redox Biol. 2023, 67, 102926. [Google Scholar] [CrossRef]
  48. Dröse, S. Differential effects of complex II on mitochondrial ROS production and their relation to cardioprotective pre- and postconditioning. Biochim. Biophys. Acta 2013, 1827, 578–587. [Google Scholar] [CrossRef]
  49. Khodaei, F.; Rashedinia, M.; Heidari, R.; Rezaei, M.; Khoshnoud, M.J. Ellagic acid improves muscle dysfunction in cuprizone-induced demyelinated mice via mitochondrial Sirt3 regulation. Life Sci. 2019, 237, 116954. [Google Scholar] [CrossRef]
  50. Dai, C.; Sharma, G.; Liu, G.; Shen, J.; Shao, B.; Hao, Z. Therapeutic detoxification of quercetin for aflatoxin B1-related toxicity: Roles of oxidative stress, inflammation, and metabolic enzymes. Environ. Pollut. 2024, 345, 123474. [Google Scholar] [CrossRef]
  51. Green, D.R.; Reed, J.C. Mitochondria and apoptosis. Science 1998, 281, 1309–1312. [Google Scholar] [CrossRef] [PubMed]
  52. Mashimo, M.; Onishi, M.; Uno, A.; Tanimichi, A.; Nobeyama, A.; Mori, M.; Yamada, S.; Negi, S.; Bu, X.; Kato, J.; et al. The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis. J. Biol. Chem. 2021, 296, 100046. [Google Scholar] [CrossRef] [PubMed]
  53. Bello, M.; Morales-González, J.A. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex. Int. J. Biol. Macromol. 2017, 105, 981–992. [Google Scholar] [CrossRef]
  54. Zhang, X.; Liu, Y.; Shen, Z.; Wang, S.; Wu, C.; Liu, D.; Tang, S.; Dai, C. Osthole ameliorates myonecrosis caused by Clostridium perfringens type A infection in mice. One Health Adv. 2023, 1, 27. [Google Scholar] [CrossRef]
  55. Gao, M.; Li, C.; Xu, M.; Liu, Y.; Cong, M.; Liu, S. LncRNA MT1DP Aggravates Cadmium-Induced Oxidative Stress by Repressing the Function of Nrf2 and is Dependent on Interaction with miR-365. Adv. Sci. 2018, 5, 1800087. [Google Scholar] [CrossRef]
  56. Ren, X.; Xu, Y.; Yu, Z.; Mu, C.; Liu, P.; Li, J. The role of Nrf2 in mitigating cadmium-induced oxidative stress of Marsupenaeus japonicus. Environ. Pollut. 2021, 269, 116112. [Google Scholar] [CrossRef] [PubMed]
  57. Wang, Q.; Botchway, B.O.A.; Zhang, Y.; Liu, X. Ellagic acid activates the Keap1-Nrf2-ARE signaling pathway in improving Parkinson’s disease: A review. Biomed. Pharmacother. 2022, 156, 113848. [Google Scholar] [CrossRef]
  58. Cao, X.; Fu, M.; Bi, R.; Zheng, X.; Fu, B.; Tian, S.; Liu, C.; Li, Q.; Liu, J. Cadmium induced BEAS-2B cells apoptosis and mitochondria damage via MAPK signaling pathway. Chemosphere 2021, 263, 128346. [Google Scholar] [CrossRef]
  59. Chen, L.; Liu, L.; Huang, S. Cadmium activates the mitogen-activated protein kinase (MAPK) pathway via induction of reactive oxygen species and inhibition of protein phosphatases 2A and 5. Free Radic. Biol. Med. 2008, 45, 1035–1044. [Google Scholar] [CrossRef]
  60. Chen, L.; Liu, L.; Luo, Y.; Huang, S. MAPK and mTOR pathways are involved in cadmium-induced neuronal apoptosis. J. Neurochem. 2008, 105, 251–261. [Google Scholar] [CrossRef]
  61. Liu, Y.; Chang, J.; Yang, C.; Zhang, T.; Chen, X.; Shi, R.; Liang, Y.; Xia, Q.; Ma, S. Genome-wide CRISPR-Cas9 screening in Bombyx mori reveals the toxicological mechanisms of environmental pollutants, fluoride and cadmium. J. Hazard. Mater. 2021, 410, 124666. [Google Scholar] [CrossRef] [PubMed]
  62. Hu, Y.R.; Ma, H.; Zou, Z.Y.; He, K.; Xiao, Y.B.; Wang, Y.; Feng, M.; Ye, X.L.; Li, X.G. Activation of Akt and JNK/Nrf2/NQO1 pathway contributes to the protective effect of coptisine against AAPH-induced oxidative stress. Biomed. Pharmacother. 2017, 85, 313–322. [Google Scholar] [CrossRef] [PubMed]
  63. Tasaki, M.; Umemura, T.; Maeda, M.; Ishii, Y.; Okamura, T.; Inoue, T.; Kuroiwa, Y.; Hirose, M.; Nishikawa, A. Safety assessment of ellagic acid, a food additive, in a subchronic toxicity study using F344 rats. Food Chem. Toxicol. 2008, 46, 1119–1124. [Google Scholar] [CrossRef]
  64. Heilman, J.; Andreux, P.; Tran, N.; Rinsch, C.; Blanco-Bose, W. Safety assessment of Urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid. Food Chem. Toxicol. 2017, 108, 289–297. [Google Scholar] [CrossRef]
  65. Ardah, M.T.; Bharathan, G.; Kitada, T.; Haque, M.E. Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinson’s Disease. Biomolecules 2020, 10, 1519. [Google Scholar] [CrossRef] [PubMed]
  66. Baluchnejadmojarad, T.; Rabiee, N.; Zabihnejad, S.; Roghani, M. Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson’s disease: Possible involvement of ERβ/Nrf2/HO-1 signaling. Brain Res. 2017, 1662, 23–30. [Google Scholar] [CrossRef]
  67. Hajiluian, G.; Karegar, S.J.; Shidfar, F.; Aryaeian, N.; Salehi, M.; Lotfi, T.; Farhangnia, P.; Heshmati, J.; Delbandi, A.A. The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial. Phytomedicine 2023, 121, 155094. [Google Scholar] [CrossRef]
Figure 1. The structure of ellagic acid (2,3,7,8-tetrahydroxychromeno (5,4,3-cde) chromene-5,10-dione, C14H6O8).
Figure 1. The structure of ellagic acid (2,3,7,8-tetrahydroxychromeno (5,4,3-cde) chromene-5,10-dione, C14H6O8).
Antioxidants 13 01296 g001
Figure 2. The cell viability and LDH level in HT22 cells exposed to ellagic acid (EA), CdSO4, or combination. A and B cells were treated with CdSO4 (at 0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) (A) or EA at various concentrations (at 2.5, 5, 10, 20, and 40 μM) (B) for 24 h, the cell viability was examined using the CCK-8 method. (C) cells were pre-treated with EA at the doses of 5, 10, or 20 μM for 2 h; then, cells were co-treated with CdSO4 at concentrations of 10, 20, or 40 μM for an additional 24 h. After treatment, the cell viability was examined using the CCK-8 method. (D) the morphology changes of HT22 cells exposed to CdSO4 treatment at 10 μM with or without EA at 20 μM. Bar = 50 μm. (E,F), the levels of LDH in the medium. HT22 cells were treated with the same conditions as cells in (A,B), respectively. All results were shown in mean ± SD (n = 3). Compared to the untreated control group, ** p < 0.01; compared to the CdSO4 only-treated group, ## p < 0.01. ns, no significant.
Figure 2. The cell viability and LDH level in HT22 cells exposed to ellagic acid (EA), CdSO4, or combination. A and B cells were treated with CdSO4 (at 0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) (A) or EA at various concentrations (at 2.5, 5, 10, 20, and 40 μM) (B) for 24 h, the cell viability was examined using the CCK-8 method. (C) cells were pre-treated with EA at the doses of 5, 10, or 20 μM for 2 h; then, cells were co-treated with CdSO4 at concentrations of 10, 20, or 40 μM for an additional 24 h. After treatment, the cell viability was examined using the CCK-8 method. (D) the morphology changes of HT22 cells exposed to CdSO4 treatment at 10 μM with or without EA at 20 μM. Bar = 50 μm. (E,F), the levels of LDH in the medium. HT22 cells were treated with the same conditions as cells in (A,B), respectively. All results were shown in mean ± SD (n = 3). Compared to the untreated control group, ** p < 0.01; compared to the CdSO4 only-treated group, ## p < 0.01. ns, no significant.
Antioxidants 13 01296 g002
Figure 3. EA supplementation attenuates CdSO4-induced cell apoptosis in HT22 cells. Cells were pre-treated with ellagic acid (EA) at final concentrations of 5, 10, or 20 μM for 2 h, then co-treated with CdSO4 at 10 μM for 24 h. (A) nuclear morphology changes were assessed using the Hoechst 33,342 staining method. Bar = 50 μm. (B) apoptotic rates were quantified through Annexin V-FITC staining combined with flow cytometry analysis. Representative images of the flow cytometry analysis (left) and quantitative results (right) are displayed. All data are presented as mean ± SD (n = 3). ** p < 0.01 compared to the control group; ## p < 0.01 compared to the CdSO4 only-treated group. The red arrow indicates chromosomal aggregation and the yellow arrow indicates nuclear fragmentation.
Figure 3. EA supplementation attenuates CdSO4-induced cell apoptosis in HT22 cells. Cells were pre-treated with ellagic acid (EA) at final concentrations of 5, 10, or 20 μM for 2 h, then co-treated with CdSO4 at 10 μM for 24 h. (A) nuclear morphology changes were assessed using the Hoechst 33,342 staining method. Bar = 50 μm. (B) apoptotic rates were quantified through Annexin V-FITC staining combined with flow cytometry analysis. Representative images of the flow cytometry analysis (left) and quantitative results (right) are displayed. All data are presented as mean ± SD (n = 3). ** p < 0.01 compared to the control group; ## p < 0.01 compared to the CdSO4 only-treated group. The red arrow indicates chromosomal aggregation and the yellow arrow indicates nuclear fragmentation.
Antioxidants 13 01296 g003
Figure 4. EA supplementation attenuates CdSO4-induced ROS production and oxidative stress damage in HT22 cells. Cells were pre-treated with ellagic acid (EA) at 5, 10, or 20 μM for 2 h, followed by co-treatment with CdSO4 at a final concentration of 10 μM for 24 h. (A) the levels of reactive oxygen species (ROS) were assessed using DCFH-DA staining in conjunction with flow cytometry analysis, with representative images displayed (on the left) and quantitative analysis (on the right). (B) levels of mitochondrial ROS in HT22 cells. Cells were pre-treated with EA at 20 μM or Mito-TEMPO at 5 μM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. Representative images (left) and quantitative results (right) are displayed. Bar = 25 μm. (C,D) antioxidant N-acetylcysteine (NAC) supplementation attenuates CdSO4 exposure-induced the production of intracellular ROS and the decrease of cell viability (D). Cells were pre-treated with NAC at a final concentration of 2.5 mM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. The ROS levels were quantified using a flow cytometry analysis (C). Cell viability was measured using the CCK-8 method (D). (E) malondialdehyde (MDA) levels. (F) the catalase (CAT) activities. (G) the superoxide dismutase (SOD) activities. All results are presented as mean ± SD (n = 3). ** p < 0.01 compared to that in the untreated control group; ## p < 0.01 compared to the CdSO4 only-treated group.
Figure 4. EA supplementation attenuates CdSO4-induced ROS production and oxidative stress damage in HT22 cells. Cells were pre-treated with ellagic acid (EA) at 5, 10, or 20 μM for 2 h, followed by co-treatment with CdSO4 at a final concentration of 10 μM for 24 h. (A) the levels of reactive oxygen species (ROS) were assessed using DCFH-DA staining in conjunction with flow cytometry analysis, with representative images displayed (on the left) and quantitative analysis (on the right). (B) levels of mitochondrial ROS in HT22 cells. Cells were pre-treated with EA at 20 μM or Mito-TEMPO at 5 μM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. Representative images (left) and quantitative results (right) are displayed. Bar = 25 μm. (C,D) antioxidant N-acetylcysteine (NAC) supplementation attenuates CdSO4 exposure-induced the production of intracellular ROS and the decrease of cell viability (D). Cells were pre-treated with NAC at a final concentration of 2.5 mM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. The ROS levels were quantified using a flow cytometry analysis (C). Cell viability was measured using the CCK-8 method (D). (E) malondialdehyde (MDA) levels. (F) the catalase (CAT) activities. (G) the superoxide dismutase (SOD) activities. All results are presented as mean ± SD (n = 3). ** p < 0.01 compared to that in the untreated control group; ## p < 0.01 compared to the CdSO4 only-treated group.
Antioxidants 13 01296 g004
Figure 5. The changes in mitochondrial function. Cells were pre-treated with ellagic acid (EA) at 5, 10, or 20 μM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. (A) the changes in mitochondrial membrane potential were evaluated using Rh123 staining and flow cytometry analysis. The representative images (left) and quantitative analysis (right) were shown. (B) the intracellular ATP levels. All results are presented as mean ± SD (n = 3). ** p < 0.01, compared to that in the untreated control group; # p < 0.05, ## p < 0.01 compared to the CdSO4 only-treated group.
Figure 5. The changes in mitochondrial function. Cells were pre-treated with ellagic acid (EA) at 5, 10, or 20 μM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. (A) the changes in mitochondrial membrane potential were evaluated using Rh123 staining and flow cytometry analysis. The representative images (left) and quantitative analysis (right) were shown. (B) the intracellular ATP levels. All results are presented as mean ± SD (n = 3). ** p < 0.01, compared to that in the untreated control group; # p < 0.05, ## p < 0.01 compared to the CdSO4 only-treated group.
Antioxidants 13 01296 g005
Figure 6. The expression of Nrf2, HO-1, p-Erk1/2, p-JNK, p-p38, Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins. Cells were pre-treated with ellagic acid (EA) at 5, 10, or 20 μM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. Protein expressions were assessed using the Western Blotting method. All results were presented as Mean ± SD (n = 3). Statistical significance levels were delineated as follows: ** p < 0.01 compared to the untreated control group; # p < 0.05 and ## p < 0.01 compared to the CdSO4 only-treated group.
Figure 6. The expression of Nrf2, HO-1, p-Erk1/2, p-JNK, p-p38, Bax/Bcl-2 ratio, cleaved caspase-3, and cleaved PARP-1 proteins. Cells were pre-treated with ellagic acid (EA) at 5, 10, or 20 μM for 2 h, followed by co-treatment with CdSO4 at 10 μM for an additional 24 h. Protein expressions were assessed using the Western Blotting method. All results were presented as Mean ± SD (n = 3). Statistical significance levels were delineated as follows: ** p < 0.01 compared to the untreated control group; # p < 0.05 and ## p < 0.01 compared to the CdSO4 only-treated group.
Antioxidants 13 01296 g006
Figure 7. Pharmacological inhibition of JNK attenuates the activation of Nrf2/HO-1 and promotes CdSO4 exposure-induced cytotoxicity. HT22 cells were treated with the JNK inhibitor SP600125 at 10 μM for 2 h, then co-treated with CdSO4 at 10 μM for an additional 24 h. (A) the changes in cell viability were assessed. (B) the protein expressions were analyzed using the Western Blotting method. All results were presented as mean ± SD (n = 3). Significance levels were indicated as follows: * p < 0.05, ** p < 0.01 compared to the untreated control group; # p < 0.05, and ## p < 0.01 compared to the CdSO4 only-treated group.
Figure 7. Pharmacological inhibition of JNK attenuates the activation of Nrf2/HO-1 and promotes CdSO4 exposure-induced cytotoxicity. HT22 cells were treated with the JNK inhibitor SP600125 at 10 μM for 2 h, then co-treated with CdSO4 at 10 μM for an additional 24 h. (A) the changes in cell viability were assessed. (B) the protein expressions were analyzed using the Western Blotting method. All results were presented as mean ± SD (n = 3). Significance levels were indicated as follows: * p < 0.05, ** p < 0.01 compared to the untreated control group; # p < 0.05, and ## p < 0.01 compared to the CdSO4 only-treated group.
Antioxidants 13 01296 g007
Figure 8. A potential proposed model of EA supplementation on CdSO4 exposure-caused apoptosis. CdSO4 exposure leads to the generation of reactive oxygen species (ROS) and lipid peroxidation while reducing the activities of antioxidant enzymes SOD and CAT, resulting in oxidative stress damage. Elevated ROS levels may disrupt mitochondrial function, triggering the activation of the mitochondrial apoptotic pathway and eventually culminating in apoptosis. Furthermore, activated JNK exerts a protective effect by stimulating the Nrf2/HO-1 pathway.
Figure 8. A potential proposed model of EA supplementation on CdSO4 exposure-caused apoptosis. CdSO4 exposure leads to the generation of reactive oxygen species (ROS) and lipid peroxidation while reducing the activities of antioxidant enzymes SOD and CAT, resulting in oxidative stress damage. Elevated ROS levels may disrupt mitochondrial function, triggering the activation of the mitochondrial apoptotic pathway and eventually culminating in apoptosis. Furthermore, activated JNK exerts a protective effect by stimulating the Nrf2/HO-1 pathway.
Antioxidants 13 01296 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liu, Y.; Chen, C.; Hao, Z.; Shen, J.; Tang, S.; Dai, C. Ellagic Acid Reduces Cadmium Exposure-Induced Apoptosis in HT22 Cells via Inhibiting Oxidative Stress and Mitochondrial Dysfunction and Activating Nrf2/HO-1 Pathway. Antioxidants 2024, 13, 1296. https://doi.org/10.3390/antiox13111296

AMA Style

Liu Y, Chen C, Hao Z, Shen J, Tang S, Dai C. Ellagic Acid Reduces Cadmium Exposure-Induced Apoptosis in HT22 Cells via Inhibiting Oxidative Stress and Mitochondrial Dysfunction and Activating Nrf2/HO-1 Pathway. Antioxidants. 2024; 13(11):1296. https://doi.org/10.3390/antiox13111296

Chicago/Turabian Style

Liu, Yue, Chunhong Chen, Zhihui Hao, Jianzhong Shen, Shusheng Tang, and Chongshan Dai. 2024. "Ellagic Acid Reduces Cadmium Exposure-Induced Apoptosis in HT22 Cells via Inhibiting Oxidative Stress and Mitochondrial Dysfunction and Activating Nrf2/HO-1 Pathway" Antioxidants 13, no. 11: 1296. https://doi.org/10.3390/antiox13111296

APA Style

Liu, Y., Chen, C., Hao, Z., Shen, J., Tang, S., & Dai, C. (2024). Ellagic Acid Reduces Cadmium Exposure-Induced Apoptosis in HT22 Cells via Inhibiting Oxidative Stress and Mitochondrial Dysfunction and Activating Nrf2/HO-1 Pathway. Antioxidants, 13(11), 1296. https://doi.org/10.3390/antiox13111296

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop